Reference number(s) 2284-H

SPECIALTY QUANTITY LIMIT PROGRAM

JAKAFI (ruxolitinib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	FDA-recommended dosing	Standard Limit
Jakafi (ruxolitinib) 5mg tablets	 Intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: The recommended starting dose of Jakafi is based on platelet count. Doses may be titrated based on safety and efficacy. The starting dose for platelet count of > 200 x 10⁹/L is 20 mg orally twice daily. The starting dose for platelet count of 100 x 10⁹/L to 200 x 10⁹/L is 15 mg orally twice daily. 	60 per 30 days
Jakafi (ruxolitinib) 10mg tablets		60 per 30 days
Jakafi (ruxolitinib) 15mg tablets	 The starting dose for platelet count of 50 x 10⁹/L to < 100 x 10⁹/L is 5 mg orally twice daily. If the response is insufficient and platelet and neutrophil counts are adequate, doses may be increased in 5 mg twice daily increments to a maximum of 25 mg twice daily. 	60 per 30 days
Jakafi (ruxolitinib) 20mg tablets	Polycythemia vera: The recommended starting dose of Jakafi is 10 mg orally twice daily. Doses may be titrated based on safety and efficacy. If response is insufficient and platelet, hemoglobin,	60 per 30 days
Jakafi (ruxolitinib) 25mg tablets	 and neutrophil counts are adequate, doses may be increased in 5 mg twice daily increments to a maximum of 25 mg twice daily. For hemoglobin of 8 to less than 10 g/dL or platelet count 50 to less than 75 x 10⁹/L: reduce dose by 5 mg twice daily. For patients on 5 mg twice daily, decrease the dose to 5 mg once daily. 	60 per 30 days

Specialty Quantity Limit Jakafi P2017.docx

© 2017 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



Reference number(s) 2284-H


III. REFERENCES

1. Jakafi [package insert]. Wilmington, DE: Incyte Corporation; March 2016.

Specialty Quantity Limit Jakafi P2017.docx

pharmaceutical manufacturers that are not affiliated with CVS Caremark.

 $\hbox{@}$ 2017 CVS Caremark. All rights reserved.



This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of